Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global plasma-derived products market was valued at USD 29,860 million in 2024 and is projected to reach USD 51,540 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period.
Plasma-derived products are therapeutic biologics manufactured from human plasma, which contains critical proteins such as immunoglobulins, clotting factors, and albumin. These products are vital for treating life-threatening conditions including hemophilia, primary immunodeficiency disorders, and autoimmune diseases. The market is segmented into immune globulin (which held a 51% revenue share in 2023), coagulation factors, albumin, and other specialized plasma proteins.
While the market demonstrates strong growth potential, it faces challenges due to the resource-intensive nature of plasma collection and stringent regulatory requirements. However, increasing global demand for immunoglobulin therapies and expanding applications in neurology and hematology are driving significant investments in plasma fractionation capacity. Geographically, North America dominates with a 40% market share, followed by Europe (24%) and China, reflecting established healthcare infrastructure and high treatment adoption rates.
Rising Prevalence of Chronic and Rare Diseases to Accelerate Market Growth
The global plasma-derived products market is witnessing significant growth due to the increasing prevalence of chronic and rare diseases that require plasma-based therapies. Conditions such as hemophilia, primary immunodeficiency disorders, and hereditary angioedema affect millions worldwide, with hemophilia A alone occurring in approximately 1 in 5,000 male births. The growing diagnosis rates of these conditions, coupled with improved healthcare access in developing regions, are creating sustained demand for plasma-derived treatments. Immunoglobulin therapies, which account for over half of the market revenue, are particularly crucial for patients with immune system deficiencies.
Technological Advancements in Plasma Fractionation to Enhance Market Potential
Recent innovations in plasma collection and processing technologies are significantly improving product yield and safety. Modern fractionation techniques can now extract more therapeutic proteins from each liter of plasma, with some advanced facilities achieving recovery rates exceeding 90% for key proteins like albumin and immunoglobulins. These efficiency gains are helping manufacturers meet the growing global demand while maintaining product affordability. Additionally, novel pathogen inactivation methods are enhancing the safety profile of plasma-derived therapies, making them more acceptable to healthcare providers and patients alike.
Furthermore, the expansion of plasma collection networks in emerging markets is creating new growth opportunities. Countries with improving healthcare infrastructure are establishing more plasma donation centers, supported by public awareness campaigns about the life-saving potential of plasma donations.
Stringent Regulatory Requirements to Limit Market Expansion
The plasma-derived products industry faces significant regulatory challenges that impact production timelines and costs. Each batch of plasma must undergo rigorous testing for pathogens, with some jurisdictions requiring up to 60 different quality control tests before release. These extensive safety protocols, while necessary, can extend the production cycle by several months and increase manufacturing costs by 20-30%. The complex approval processes for new plasma collection centers further constrain the industry's ability to quickly scale up production in response to growing demand.
Plasma Supply Chain Vulnerabilities to Challenge Market Stability
The industry's reliance on human plasma donations creates inherent supply chain risks that can disrupt product availability. Natural disasters, pandemics, or geopolitical conflicts can significantly impact donation rates and plasma collection volumes. The COVID-19 pandemic demonstrated this vulnerability, with plasma collections declining by approximately 15-20% during peak infection periods in many regions. Such fluctuations can lead to product shortages, particularly for therapies with limited alternative treatment options, potentially putting patients at risk and creating market instability.
Emerging Markets Present Significant Growth Potential
Developing economies represent a substantial growth opportunity for plasma-derived products, with markets in Asia-Pacific and Latin America projected to grow at nearly double the global average rate. Increasing healthcare expenditure in these regions, coupled with improving diagnosis rates for conditions requiring plasma therapies, is creating new demand. Several countries are investing in local plasma fractionation capabilities to reduce dependence on imports, with some Asian nations planning to increase plasma collection volumes by 50% over the next five years.
Expansion into New Therapeutic Areas to Drive Innovation
Research into novel applications for plasma-derived products is uncovering potential treatments for neurological disorders, infectious diseases, and wound healing. Clinical trials are exploring the efficacy of immunoglobulins in conditions ranging from Alzheimer's disease to chronic fatigue syndrome. If successful, these new indications could significantly expand the addressable market for plasma therapies. The development of hyperimmune globulins for emerging infectious diseases also presents a promising avenue for growth, particularly given the lessons learned from recent global health crises.
High Production Costs to Constrain Market Accessibility
The capital-intensive nature of plasma product manufacturing presents a significant challenge to market growth. Establishing a plasma fractionation facility requires investments exceeding $500 million, with operational costs remaining high due to the need for specialized equipment and highly trained personnel. These costs ultimately translate into high treatment prices, creating accessibility issues in price-sensitive markets. Some immunoglobulin therapies can cost patients over $100,000 annually, presenting challenges for healthcare systems and insurers seeking to balance budgets while providing necessary treatments.
Competition from Alternative Therapies to Impact Market Dynamics
The development of recombinant alternatives and gene therapies is creating competitive pressure on traditional plasma-derived products. While plasma therapies remain essential for many conditions, novel treatments offering longer dosing intervals or potential cures are gaining traction. For hemophilia, gene therapies in development could reduce or eliminate the need for regular factor replacement, potentially impacting a significant portion of the plasma products market. Manufacturers must balance investment in traditional therapies with innovation to remain competitive in this evolving treatment landscape.
The global plasma-derived products market is experiencing significant growth, primarily due to the increasing demand for immunoglobulin therapies, which accounted for 51% of the market share in 2023. These therapies are vital for treating autoimmune disorders, neurological conditions, and primary immunodeficiency diseases. With the prevalence of immune deficiencies rising steadily, particularly in North America and Europe, manufacturers are scaling up production to meet patient needs. Advances in purification technologies have enhanced product safety and efficacy, further boosting adoption rates. Furthermore, regulatory agencies continue to streamline approval processes for novel plasma-derived therapies, accelerating market expansion.
Expansion of Plasma Collection Centers
The plasma-derived products market is witnessing a surge in specialized collection centers globally, ensuring a stable supply of raw plasma. North America leads with nearly 40% of total market revenue, driven by well-established infrastructure and high donor participation. However, emerging markets in Asia, particularly China, are rapidly increasing plasma collection efforts, supported by government incentives and improved healthcare policies. While plasma sourcing remains complex due to stringent donor screening requirements, automated collection systems are now minimizing processing times and improving efficiency.
Plasma-derived products are increasingly being leveraged for rare disease treatments, particularly in hematology and neurology. Conditions like hemophilia and alpha-1 antitrypsin deficiency rely heavily on therapies such as coagulation factors and albumin, which collectively represent over 30% of product applications. Pharmaceutical companies are actively expanding their portfolios through strategic mergers and acquisitions, enhancing their capabilities in fractionation technologies. Meanwhile, research into hyperimmune globulins for emerging infections has opened new revenue streams, with several products in late-stage clinical trials. The growing emphasis on orphan drug designations is also encouraging manufacturers to invest in niche therapeutic areas.
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the Plasma-derived Products market is moderately consolidated, featuring a mix of large multinational corporations, mid-sized regional players, and smaller specialized firms. This structure fosters innovation while intensifying rivalry, particularly in plasma collection, fractionation, and product development. CSL Limited, headquartered in Australia, stands out as a dominant force, leveraging its extensive global network of plasma collection centers and a robust portfolio of immunoglobulins and coagulation factors. With operations spanning over 30 countries, CSL commands a significant market share, driven by its commitment to high-volume plasma sourcing and advanced manufacturing technologies that ensure product safety and efficacy.
Grifols, S.A. and Takeda Pharmaceutical Company Limited also captured substantial portions of the market in 2024, together accounting for a notable percentage of global revenues. Their success stems from strategic acquisitions and investments in R&D, which have expanded their offerings in immune globulins and albumin products. For instance, immune globulins, which held about 51% of the market share in 2023, remain a key focus, addressing rising demands for treatments in primary immunodeficiency and autoimmune disorders. These companies benefit from strong end-user relationships in hospitals and specialty clinics, where plasma-derived therapies are increasingly prescribed.
Furthermore, ongoing growth strategies, including expansions into emerging markets like Asia-Pacific and Latin America, alongside frequent new product launches, are poised to elevate their positions through the forecast period ending in 2031. The global market, valued at approximately $29,860 million in 2024 and projected to reach $51,540 million by 2031 at a CAGR of 8.1%, underscores the potential for these initiatives to drive further consolidation and market penetration. However, challenges such as supply chain vulnerabilitiesexacerbated by past events like the COVID-19 pandemic that reduced plasma collectionscontinue to test resilience, prompting investments in diversified sourcing and alternative therapies.
Meanwhile, players like Octapharma AG and Kedrion S.p.A. are bolstering their footholds via substantial R&D expenditures, collaborations with healthcare providers, and enhancements in product purification processes. These efforts not only mitigate regulatory hurdles but also address the high costs of plasma sourcing, ensuring sustainable growth amid stringent safety standards. Octapharma, for example, has emphasized innovations in factor VIII concentrates for hemophilia treatment, aligning with the increasing prevalence of rare diseases that fuel overall demand. As North America dominates with nearly 40% of global consumption in 2023, followed by Europe's 24% share, these companies are strategically positioning themselves to capitalize on regional healthcare investments and aging populations that heighten needs for chronic condition management.
The global plasma-derived products market, encompassing medicinal products manufactured from human plasma such as clotting factors, immunoglobulins, and albumin, is experiencing steady growth driven by the rising incidence of chronic and rare diseases. Valued at $29,860 million in 2024, the market is projected to reach $51,540 million by 2031, reflecting a compound annual growth rate (CAGR) of 8.1% during the forecast period. These products are critical for treating conditions like hemophilia, primary immunodeficiency disorders, and autoimmune diseases, where plasma proteins play a vital role in therapy.
Plasma-derived products (PDPs) are derived from the liquid component of human blood, containing essential proteins, clotting factors, and antibodies that are fractionated and purified for medical use. They are indispensable in managing bleeding disorders, immune deficiencies, and volume replacement needs in critical care. The market's expansion is supported by advancements in fractionation technologies and increasing global awareness of plasma-based therapies. However, supply chain vulnerabilities highlight the importance of robust donor programs and regulatory compliance.
A primary driver of the plasma-derived products market is the escalating prevalence of rare and chronic diseases requiring long-term treatments, including hemophilia and autoimmune conditions. Enhanced diagnostic capabilities and growing healthcare investments, particularly in emerging markets, are boosting demand for immunoglobulins, clotting factors, and albumin. Technological improvements in plasma collection and processing have also enhanced product safety and availability, contributing to broader adoption in clinical settings worldwide.
The plasma-derived products market faces significant hurdles due to the intricate and resource-intensive nature of plasma sourcing and manufacturing. Reliance on human donors necessitates rigorous screening and testing protocols to mitigate risks, driving up costs and extending production timelines. Supply disruptions, exemplified by the COVID-19 pandemic's impact on blood and plasma donations, have led to raw material shortages, underscoring the need for diversified supply chains and contingency planning to ensure uninterrupted therapy access.
Immune Globulin Segment Dominates the Market Due to its Critical Role in Immunotherapy and High Demand for Immune Deficiency Treatments
The market is segmented based on type into:
Immune globulins lead the segment with a substantial market share, driven by their widespread use in treating primary immunodeficiencies and autoimmune disorders. Coagulation factors remain essential for hemophilia management, while albumin supports critical care applications like shock treatment and surgery. The 'Others' category includes specialized products addressing niche therapeutic needs, reflecting the diverse applications of plasma-derived therapies.
Hospital Segment Leads Due to Extensive Use in Inpatient Care and Emergency Treatments
The market is segmented based on application into:
Hospitals dominate applications owing to the high volume of plasma-derived products administered in acute settings for conditions such as trauma and immune disorders. Retail pharmacies facilitate outpatient access, particularly for chronic therapies like immunoglobulins, while the 'Other' category encompasses uses in clinics and home care, supporting the shift toward decentralized healthcare delivery.
North America holds the largest market share at nearly 40% in 2023, bolstered by advanced healthcare infrastructure and strong plasma collection networks. Europe follows with 24%, emphasizing regulatory standards and established therapies. Asia, particularly China, emerges as a key growth area due to expanding patient populations and investments in biopharmaceuticals, though challenges in supply persist across regions.
Leading companies in the plasma-derived products market include:
These firms are pivotal in driving innovation, with focuses on expanding production capacities and enhancing product portfolios to meet global demand.
The plasma-derived products market presents robust growth opportunities amid rising disease burdens, tempered by supply and regulatory complexities. Stakeholders should prioritize sustainable sourcing and technological advancements to capitalize on the projected expansion through 2031.
North America
North America dominates the global plasma-derived products market, holding nearly 40% of the revenue share in 2023, driven by advanced healthcare infrastructure and high prevalence of chronic and rare diseases such as hemophilia and primary immunodeficiency disorders. The United States, in particular, leads due to robust plasma collection networks and significant investments in biotechnology, with major players like CSL and Grifols operating extensive facilities that ensure a steady supply of essential products including immunoglobulins, which captured 51% of the global market in 2023. Furthermore, the region's stringent regulatory framework enforced by the FDA ensures product safety and efficacy, fostering trust among healthcare providers and patients alike. However, challenges persist, notably the high cost of manufacturing, which relies on human plasma donationsa process complicated by donor screening and testing protocols that drive up expenses. The COVID-19 pandemic exacerbated supply shortages by reducing blood and plasma donations, yet recovery has been swift thanks to government initiatives promoting plasma therapies for immune support. Looking ahead, increasing awareness and diagnosis rates, coupled with ongoing advancements in fractionation technologies, are projected to sustain growth at a CAGR aligned with the global 8.1% through 2031. In Canada and Mexico, similar trends emerge, though on a smaller scale; Canada's universal healthcare system boosts accessibility, while Mexico focuses on expanding hospital networks to meet rising demand for coagulation factors and albumin in treating autoimmune conditions. Overall, North America's market resilience stems from its innovation ecosystem, where companies invest heavily in R&D to develop next-generation plasma-derived therapies, addressing unmet needs in critical care. This region's emphasis on personalized medicine and telemedicine further enhances product utilization, particularly in retail pharmacies and hospitals, which form the primary distribution channels. While economic factors like reimbursement policies influence adoption, the overarching driver remains the growing burden of lifestyle-related diseases requiring long-term immunoglobulin treatments. As a result, stakeholders anticipate continued expansion, with opportunities in emerging therapies for neurological disorders.
Europe
Europe represents the second-largest market for plasma-derived products, accounting for about 24% of global revenue in 2023, underpinned by a well-established healthcare system and strict regulatory standards under the European Medicines Agency (EMA). Countries like Germany, France, and the U.K. are at the forefront, benefiting from high diagnosis rates of rare diseases and a mature network of plasma fractionation centers operated by firms such as Octapharma and Kedrion. The demand for immune globulins and coagulation factors is particularly strong, driven by an aging population that increases the incidence of conditions like hemophilia and autoimmune diseases. However, the region faces supply chain vulnerabilities, as plasma collection depends on voluntary donations amid fluctuating donor participation, a issue highlighted during the COVID-19 crisis when collections dropped significantly, leading to temporary shortages. Despite this, Europe's focus on sustainability and ethical sourcing has spurred investments in advanced collection technologies, mitigating some risks. The market's growth is also fueled by government support for rare disease treatments, including funding for research into albumin-based therapies for critical care. In Eastern Europe, such as Russia and Italy, adoption is growing but hampered by economic disparities and varying regulatory enforcement. Innovation remains a key pillar, with collaborations between biotechs and pharma giants aiming to enhance product purity and yield from limited plasma volumes. Furthermore, the push toward self-sufficiency in plasma supply, as seen in the EU's plasma master plan, addresses dependency on imports and supports local manufacturing. Hospitals dominate distribution, with retail pharmacies gaining traction for outpatient immunoglobulin infusions. Challenges include high production costs and competition from recombinant alternatives, yet plasma-derived products' established efficacy ensures their relevance. As urbanization advances, especially in Nordic and Benelux countries, demand for these therapies is expected to rise, aligning with the global projection to reach $51,540 million by 2031. Europe's balanced approach to regulation and innovation positions it for steady, sustainable growth in this vital sector.
Asia-Pacific
The Asia-Pacific region is a dynamic growth hub for plasma-derived products, with China emerging as a critical sales area due to its vast population and expanding healthcare infrastructure, contributing significantly to the region's rising market share. Rapid urbanization and increasing prevalence of chronic diseases, including primary immunodeficiencies and hemophilia, drive demand for products like immune globulins and coagulation factors, which see heightened use in hospitals and emerging retail pharmacy networks. Japan and South Korea add maturity to the market through advanced biotech capabilities, where companies like Takeda and KM Biologics innovate in fractionation processes to improve efficiency and safety. However, challenges abound, particularly the costly and complex plasma collection reliant on donor pools that were severely impacted by COVID-19, resulting in raw material shortages that slowed growth temporarily. In India and Southeast Asia, cost sensitivity favors affordable options, though a shift toward premium plasma-derived therapies is underway, supported by government investments in healthcare and awareness campaigns for rare diseases. The region's market benefits from a young demographic and improving diagnostics, leading to higher treatment rates for autoimmune conditions requiring albumin. Supply chain disruptions from geopolitical tensions pose risks, but local production ramps up, as evidenced by Chinese firms like Hualan Bio expanding capacities. Overall, Asia-Pacific's growth trajectory mirrors the global CAGR of 8.1%, propelled by economic development and policy reforms enhancing reimbursement for these essential medicines. While conventional challenges like regulatory harmonization persist, the potential for blue ocean markets in underserved areas offers opportunities for key players to penetrate deeper. With infrastructure projects boosting hospital access, particularly in India and China, the demand for plasma-derived products is set to surge, focusing on long-term therapies that address the region's evolving health landscape.
South America
South America presents an emerging yet promising landscape for the plasma-derived products market, where Brazil and Argentina lead in adoption amid gradual healthcare advancements and rising awareness of rare and chronic diseases such as hemophilia and immune deficiencies. The region's demand for immune globulins, holding a dominant 51% global share, is growing due to improving diagnostic capabilities and increasing hospital integrations, though economic volatility often limits widespread access. Supply challenges are acute, with plasma collection hampered by donor shortages and the lingering effects of COVID-19, which reduced donations and strained manufacturing, leading to reliance on imports from North American and European suppliers like Grifols and CSL. Government initiatives in Brazil, for instance, aim to bolster local production through investments in fractionation facilities, addressing the high costs associated with stringent donor screening and testing. In Argentina and other nations, autoimmune disease treatments drive albumin and coagulation factor usage, but limited regulatory enforcement and funding constraints slow progress. Retail pharmacies are expanding as a distribution channel, offering opportunities for outpatient care, yet affordability remains a barrier in rural areas. The market's potential lies in demographic shifts, with a growing middle class seeking advanced therapies, supported by international partnerships that transfer technology and knowledge. However, geopolitical and economic instability poses risks to supply chains, potentially exacerbating shortages. Despite these hurdles, the focus on public health programs for rare diseases signals long-term viability, aligning with global trends toward enhanced plasma therapies. As infrastructure develops, South America's market could see accelerated growth, particularly if domestic capabilities strengthen to meet the projected global expansion to $51,540 million by 2031, fostering self-reliance and better patient outcomes across the region.
Middle East & Africa
The Middle East and Africa region is in the nascent stages of the plasma-derived products market, with infrastructure development in countries like Saudi Arabia, UAE, and Turkey creating initial demand for treatments addressing hemophilia, immunodeficiencies, and autoimmune diseases. Immune globulins and coagulation factors are key, though adoption lags due to funding limitations and weak regulatory frameworks that complicate safe plasma collection and distribution. The COVID-19 pandemic intensified challenges by slashing donation rates, resulting in acute shortages and highlighting vulnerabilities in supply chains heavily dependent on imports from established markets. In Israel and select African nations, growing healthcare investments support hospital-based usage, while retail pharmacies emerge in urban centers to facilitate access to albumin for critical care. Economic disparities hinder progress, yet rising urbanization and chronic disease prevalence, driven by lifestyle changes, offer growth prospects. Local players and international firms like Takeda are exploring partnerships to build fractionation capacities, mitigating high manufacturing costs through technology transfers. Government efforts in the Gulf states, such as Saudi Vision 2030, prioritize biotech advancements, potentially boosting domestic production and reducing import reliance. Challenges include geopolitical issues disrupting logistics and limited donor awareness, but educational campaigns could reverse this trend. The region's market aligns with global drivers like disease awareness, positioning it for expansion at the 8.1% CAGR, particularly as emerging economies invest in universal health coverage. Long-term, increased urban development and international aid will likely enhance availability of plasma-derived therapies, turning potential risks into opportunities for sustainable market penetration and improved health equity.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
The global Plasma-derived Products market was valued at USD 29,860 million in 2024 and is projected to reach USD 51,540 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period. Historical data from 2020 to 2024 indicates consistent expansion, driven by rising demand for therapies treating rare diseases. Regionally, North America dominates with a 40% revenue share in 2023, followed by Europe at 24%. Asia-Pacific, particularly China, is emerging as a significant market due to increasing healthcare investments.
Growth trends reflect a surge in volume and value, with projections estimating annual increases fueled by higher diagnosis rates of conditions like hemophilia and immunodeficiencies. Value projections align with the overall CAGR, while volume growth is supported by expanded plasma collection capacities worldwide, ensuring sustained supply for product manufacturing.
Segmentation Analysis
By product type, the market is segmented into Immune Globulin, Coagulation Factor, Albumin, and Others. In 2023, Immune Globulin held the largest share at 51%, owing to its critical role in treating primary immunodeficiency disorders and autoimmune conditions. Coagulation Factors follow, essential for hemophilia management, while Albumin supports critical care applications.
By application, segments include Hospital, Retail Pharmacy, and Other. Hospitals represent the primary usage area, accounting for the majority of consumption due to acute treatment needs. Retail Pharmacy is growing with increased patient access to home-based therapies.
By end-user industry, the market serves pharmaceutical and biotech sectors, focusing on healthcare providers treating chronic diseases. No specific distribution channels are prominently defined, though direct supply to hospitals and pharmacies prevails.
Regional Insights
North America leads the market, with the United States contributing the bulk of revenue due to advanced healthcare infrastructure and high prevalence of treated conditions. Europe follows, with key countries like Germany, France, and the U.K. driving demand through robust regulatory frameworks. Asia-Pacific shows rapid growth, led by China and Japan, supported by rising disposable incomes and government initiatives. Latin America and Middle East & Africa present untapped potential amid improving access to biologics.
Country-level data highlights the U.S. as the top market in North America, Germany in Europe, China in Asia-Pacific, Brazil in Latin America, and Saudi Arabia in the Middle East & Africa, each projected to grow at varying CAGRs aligned with regional trends through 2031.
Competitive Landscape
Major players include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio, Tiantan Bio, Shuanglin Bio, Boya Bio, Yuanda Shuyang, Weiguang Bio, Nanyue Bio, and KM Biologics. These companies collectively hold significant market share, with the top five accounting for over 50% in 2024. Takeda and CSL lead in revenue, focusing on global expansion.
Key strategies encompass mergers and acquisitions, such as Grifols' recent partnerships for supply chain enhancement, and expansions into emerging markets. Product portfolios feature comprehensive PDP lines, with pricing strategies balancing high manufacturing costs and accessibility, often through volume-based discounts for healthcare providers.
Technology & Innovation
Emerging technologies include advanced plasma fractionation methods and recombinant alternatives, though PDPs remain vital. R&D trends focus on improving yield and purity, with investments in nanotechnology for better protein isolation.
Automation in plasma collection centers and digitalization of supply tracking enhance efficiency. Sustainability initiatives emphasize ethical donor programs and waste reduction in manufacturing. While AI and IoT are not direct disruptors, they support predictive analytics for demand forecasting and quality control in production processes.
Market Dynamics
Key drivers include the rising prevalence of rare and chronic diseases like hemophilia and immunodeficiencies, boosting demand for clotting factors and immunoglobulins. Advancements in collection technologies and healthcare investments in emerging markets further propel growth.
Restraints involve high production costs and regulatory hurdles for donor screening, alongside supply disruptions from pandemics like COVID-19, which reduced collections and caused shortages.
Supply chain trends feature global sourcing of plasma, with challenges in logistics and geopolitical stability affecting availability. Efforts to diversify sources mitigate risks.
Opportunities & Recommendations
High-growth segments include Immune Globulins and applications in hospitals, driven by aging populations and chronic disease management.
Investment hotspots are Asia-Pacific and Latin America, where infrastructure development offers expansion potential.
Strategic suggestions for stakeholders involve partnering for R&D in efficient fractionation, expanding into underserved regions, and adopting sustainable practices to ensure long-term supply security.
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
-> The global plasma-derived products market was valued at USD 29,860 million in 2024 and is projected to reach USD 51,540 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period.
Which key companies operate in Global Plasma-derived Products Market?
-> Key players include Takeda, CSL, Grifols, Octapharma, Kedrion, among others.
-> Key growth drivers include increasing prevalence of rare and chronic diseases, advancements in plasma technologies, and healthcare investments.
-> North America dominates with nearly 40% share, while Asia-Pacific is the fastest-growing region.
-> Emerging trends include improved fractionation technologies, sustainable plasma sourcing, and expanded applications in immunotherapy.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates